Early and long-term outcomes of minimally invasive mitral valve surgery through right minithoracotomy: a 10-year experience in 1604 patients

Mattia Glauber†, Antonio Miceli†*, Daniele Canarutti, Antonio Lio, Michele Murzi, Daniyar Gilmanov, Matteo Ferrarini, Pier A. Farneti, Eugenio L. Quaini and Marco Solinas

Abstract
Background: To report early and long-term outcomes of patients undergoing minimally invasive mitral valve surgery (MIMVS) through right mini-thoracotomy (RT) over a 10-year period.

Methods: From September 2003 to December 2013, a total of 1604 consecutive patients underwent MIMVS through RT.

Results: The mean age was 63 ± 13 years, 770 (48 %) patients were female and 218 (13.6 %) had previous cardiac operations. The most predominant pathology was degenerative disease (70 %), followed by functional mitral valve regurgitation (12 %), rheumatic disease (9.4 %), endocarditis (5 %) and prosthetic dysfunction (3.2 %). Mitral valve repair was performed in 1137 (71 %) patients and 476 (29 %) had mitral valve replacement. Direct aortic cannulation was achieved in 1325 (83 %) patients. Among patients with degenerative disease candidate for repair (n = 958), rate of mitral valve repair was 95 %. Repair techniques included annuloplasty (95 %), leaflet resection (63 %), neochordae implantation (16 %) and sliding plasty (11 %). Concomitant procedures included tricuspid valve repair (14.6 %), atrial fibrillation ablation (9.5 %) and atrial septal defect closure (3.2 %). Overall in-hospital mortality was 1.1 %. Thirty-four patients (2.1 %) had conversion to sternotomy. Incidence of stroke was 2 %. Overall survival at 10 years was 88 ± 2 %. Freedom from reoperation at 10 years was 94 ± 2 % for repair and 80 ± 6 % for replacement. Freedom from recurrent mitral regurgitation >3+ at 10 years was 90 ± 3 %.

Conclusions: Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality and morbidity, high rate of mitral valve repair and excellent late results.

Keywords: Minimally invasive mitral valve surgery, Mitral valve

Background
Mitral valve surgery using conventional full sternotomy (FS) is the conventional approach for the treatment of the mitral valve disease. Despite this procedure has shown excellent postoperative outcomes, in the last two decades minimally invasive mitral valve surgery (MIMVS) has gained consensus among surgeons as it has provided greater patients satisfaction, maintaining the same quality and safety of the standard mitral valve surgery approach [1, 2].

According to a statement from the American Heart Association, the term “minimally invasive” refers to a small chest wall incision that does not include a FS [3]. The most common MIMVS approach is the right thora-cotomy (RT) followed by the partial sternotomy. Compared with conventional surgery, MIMVS has been shown excellent results in terms of mortality, morbidity and pain, providing shorter hospital stay, faster recovery and return to normal activities which translate into less use of rehabilitation resources and healthcare costs [4–10]. Although these benefits, criticisms have
been raised as MIMVS is technically more complex, requires a distinct learning curve and is associated with higher incidence of neurological events, aortic dissection, groin complications and higher rate of mitral valve replacement instead of mitral valve repair [5, 11]. Since 2003, we started our MIMVS program and after few years, RT approach has become the standard approach for the treatment of mitral valve disease. The aim of our study is to report early and long-term outcomes of consecutive patients who had undergone mitral valve surgery using RT during a 10-year period.

**Methods**

**Patient selection and data collection**

A retrospective, observational study was undertaken of prospectively collected data in 1800 consecutive patients undergoing mitral valve surgery, of which 1604 underwent MIMVS through RT between September 2003 and December 2013 (Fig. 1). One hundred and ninety-six procedures were performed in sternotomy. The main reason for performing a sternotomy approach was the selection patient for the learning curve, and in case of very poor left ventricular ejection fraction, strong pleural adhesions, severe chronic obstructive pulmonary disease and active endocarditis with abscess involving the mitro-aortic continuity. The ethical committee approved the study, and individual consent was waived. The data collection form was entered in a local database and included three sections completed consecutively by the cardiac surgeons, anaesthetists and perfusionists involved in the care of the patients.

The main outcomes investigated were early and late mortality, perioperative complications, and freedom from MR recurrence and reoperation.

Early mortality was defined as any death occurring within 30 days of operation or before discharge from the hospital. Stroke was defined as any new focal or global neurological deficit lasting more than 24 h, and were confirmed whenever possible by neurologists and neuroradiologists. Postoperative stroke was diagnosed if evidence was found of a new neurologic deficit with morphologic substrate confirmed by computed tomography or nuclear magnetic resonance imaging.

Acute kidney injury was defined as postoperative creatinine increase of 1+ mg/dl or requirement of haemodialysis. Perioperative myocardial infarction was defined as maximum creatine kinase MB elevation three times above the upper normal level and new Q waves >0.04 ms and/or reduction in R waves >25 % in at least two contiguous leads in the electrocardiogram or the proof of new wall motion disturbances in the echocardiogram. Pulmonary complications included ventilation failure, reintubation and tracheostomy.

All patients were seen 8 to 12 weeks postoperatively and thereafter were contacted for follow-up data. The median follow-up time was 32 months (interquartile range 9–59 months) and the follow-up data were 96.6 % complete.

All patients had a preoperative transthoracic echocardiography as well as at discharge. The severity of mitral regurgitation was graded following the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery recommendations [12]. Echocardiographic follow-up consisted of those patients who survived and had postoperative echocardiogram more than 6 months (812/1492, 52 %) at a median of 15 months (IQR 6–51) after surgery. Recurrent MR was defined as moderate or severe on a 4-point grade: trivial, 1 of 4; mild, 2 of 4; moderate, 3 of 4; and severe, 4 of 4.

**Surgical technique**

The standardized surgical approach for MIMVS has been reported elsewhere [13]. Briefly, MIMVS by a way of right anterior thoracotomy was performed through a 5–7 cm skin incision placed at 3th or 4th intercostal space. After incision a soft tissue retractor is inserted and the intercostal space is gently spread with a retractor. Two trocars are inserted in the thorax to allow positioning of a ventricular vent, CO2 insufflator, camera device and pericardial stay sutures. Whereas at the beginning of our experience the approach involved retrograde arterial perfusion and balloon endoclamping, the procedure has evolved to a technique with ascending aorta cannulation, long femoral venous cannula drainage, and direct transthoracic aortic clamping. Specifically, direct aortic cannulation was performed using Easyflow (Sorin, Salluggia, Italy) or Straightshot (Edwards Lifesciences, Irvine, Calif) cannulas. Biomedicus single stage (Medtronic, Minneapolis, Minn) or RAP single 2 stage cannulas (Estech) were inserted through the femoral vein into the right atrium and the correct position was
achieved with the Seldinger technique under transesophageal echocardiographic guidance. In case of mitral and tricuspid valve surgery, a single 2 stage cannula (RAP, Estech) was used as it allows to drain simultaneously the superior and inferior venae cavae. After vacuum-assisted cardiopulmonary bypass (∼40 to ∼60 mmHg) was established, the patients were cooled to 34 °C. The ascending aorta was clamped with the Cygnet crossclamp (ovare surgical System, Cupertino, Calif) or with the aortic Glauber clamp (Cardiomedical GmbH, Langenhagen, Germany; distributed by sorin, Salluggia, Italy) and antegrade cold crystalloid or warm blood cardioplegia is delivered directly into the ascending aorta by a needle vent catheter.

The mitral valve is approached with a traditional left paraseptal atriotomy and exposed using a specially designed atrial retractor held by a mechanical harm inserted through a right parasternal port. Mitral valve procedures were performed under a combination of direct vision and thoracoscopic assistance. The surgical steps that we were unable to perform under direct vision were performed with video assistance, such as placement of sutures on the anterior annulus of the mitral valve, or at the level of the posterior medial commissures. In the setting of degenerative mitral valve disease, mitral valve repair was the first approach for the degenerative mitral valve repair; mitral valve replacement was commonly used in presence of severe annulus and/or leaflet calcifications and patients older than 80 with complex complex repair. All patients received an accurate intraoperative transesophageal echocardiogram before and after weaning from cardiopulmonary bypass machine. In patients who had an attempt to repair, our policy is to replace the mitral valve if a) at the hydrostatic saline test after several attempts, there is still some degrees of mitral regurgitation, b) the surface of coaptation is not enough to guarantee a long durability, c) at intraoperative echo, there is more than mild mitral regurgitation.

Eight surgeons contributed to this series, with 2 of them (MG, MS) performing 59.2 % of the operations.

Statistical analysis
Continuous data were expressed as mean ± standard deviation or median with the interquartile range and categorical data as percentages. Cumulative survival was evaluated with the Kaplan–Meier method. All reported P values are two-sided, and P values of <0.05 were considered to indicate statistical significance. All statistical analyses were performed with SPSS 22.0 (SPSS, Inc., Chicago, IL, USA).

Results
Baseline characteristics are listed in Table 1. The mean age was 63 ± 13 years, 770 (48 %) patients were female and 215 (13.4 %) had previous cardiac operations. The mean body mass index was 25 ± 4.8 Kg/m². The mostpredominant pathology was degenerative disease (n = 1114, 70 %), followed by functional mitral valve regurgitation (n = 191, 12 %), rheumatic disease (n = 151, 9.4 %), endocarditis (n = 80, 5 %) and prosthetic dysfunction (3.2 %), Table 2. Mitral valve repair was performed in 1137 (71 %) patients and 476 (29 %) had mitral valve replacement (Table 2). Direct aortic cannulation was achieved in 1325 (83 %) patients. In 1432 (89.9 %) of cases, the aorta was cross-clamped; in 130 (8.1 %) an endo-aortic balloon was used, and in 43 (2.7 %), operations were performed in beating heart or ventricular fibrillation.

Median CBP time was 131 (IQR 109–162) min, and median cross-clamp time was 88 min (IQR 69–112). Concomitant procedures included tricuspid valve repair (n = 234, 14.6 %), atrial fibrillation ablation (n = 152, 9.5 %) and atrial septal defect closure (n = 51, 3.2 %).

Early outcomes
Overall in-hospital mortality was 1.1 % (n = 19, predicted median EuroSCORE 6 %, interquartile range 3–14 %). Thirty-four patients (2.1 %) had conversion to sternotomy either because of bleeding (21, 1.3 %), strong adherions (9, 0.5 %), aortic dissection due to the use of endoclamp (4, 0.25 %); 23 (1.4 %) patients required an IABP. Incidence of stroke, transient ischemic attack and acute renal failure requiring dialysis was 2 % (n = 32), 0.25 % (n = 4) and 1.3 % (n = 21). Twenty-three patients (1.4 %) had myocardial infarction, 41 patients (2.5 %) had pulmonary complications and rate of pacemaker implantation was 3.3 % (n = 53). Mean ICU stay was 1 day (IQR 1.0–1.0), and mean ward stay was 6 days. 951 (59.3 %) patients were discharged home. Postoperative outcomes are reported in Table 3.

Mitral valve repair
Out of 1210 candidates for valve repair, 1137 were effectively repaired (94 %), while 73 (6 %) required replacement after a repair attempt. Repair techniques included annuloplasty (95 %), either alone (264/1137, 23.2 %) or with another repair technique (814/1137, 71.6 %), including leaflet resection (63 %), neochordae implantation (16 %), and sliding plasty (11 %). For the 1137 patients that were effectively repaired, 19 (1.7 %) required conversion to full sternotomy and 29 (2.5 %) had to be reoperated for evidence, at pre-discharge echocardiography, of significant mitral regurgitation: in 12 cases the valve was replaced; in the remaining 17 (59 %) the valve was effectively re-repaired.

After repair, residual MR at discharge was very low (no MR: 803 (72.6 %), trivial: 264 (23 %), mild: 38 (3.3 %), moderate MR: 1 (0.08 %).
Out of 1114 patients affected by a degenerative mitral valve disease, 958 (86 %) of them were candidates for repair; successful repair rate was 94.7 % (907/958). Out of the remaining 156 patients, 80 were not deemed amenable to repair because of previous operation on the valve \( n = 32 \) or severe calcifications (involving annulus and/or leaflets \( n = 48 \)). In the remaining 76 cases, the learning curve was considered the main cause.

**Mitral valve replacement**

Mitral valve replacement was performed in 467 patients. The predominant pathologies were degenerative \( n = 207, 44.3 \% \) and rheumatic \( n = 134, 28.7 \% \). Other entities were functional regurgitation \( n = 36 \), ischemic regurgitation \( n = 24 \), active \( n = 10 \) endocarditis, prosthesis dysfunction \( n = 28 \), congenital valve disease \( n = 2 \), and other \( n = 7 \). Mechanical and biological prosthesis was implanted in 224 (48 \%) and 243 (52 \%), respectively. As previously stated, 73 replacements were failed repairs.

**Late outcomes**

Median follow-up time was 32 months (IQR 9–59) and was 96.6 \% complete. At follow-up, 114 patients were dead: 61 patients were MVR and 53 were mitral valve repair.

### Survival

Overall 1-, 5- and 10-year survival were 96.3 ± 0.5 \%, 88.9 ± 1.1 \%, and 84.5 ± 1.8 \% respectively, Fig. 2a. Specifically, survival after repair at 1-, 5- and 10-years was 98.5 ± 0.4 \%, 91.9 ± 1.2 \%, and 88.0 ± 2.1 \% respectively. Survival after replacement at 1-, 5- and 10-years was 91.1±1.4 \%, 81.3 ± 2.5 \%, and 76.2 ± 3.4 \% respectively, Fig. 2b.

In the setting of degenerative mitral valve disease, overall 1-, 5-, and 10-year survival was 98.1 ± 0.4 \%, 91.8 ± 1.2 \%, and 88.1 ± 1.9 \% respectively, Fig. 2c. Specifically, rate of survival after mitral valve repair was 99.2 ± 0.3 \% at 1 year, 93.5 ± 1.3 \% at 5 years and 90.1 ± 2 \% at 10 years, whereas survival after mitral valve replacement was 92.7 ± 1.8 \% at 1 year, 84.4 ± 3.2 \% at 5 year, and 79.3 ± 4.6 \% at 10 year, respectively Fig. 2d. Overall 1-, 5- and 10-year survival were 94.3 ± 1.7 \%, 83.8 ± 3.8 \% and 81.2 ± 4.5 \% for patients who received a mechanical valve

### Table 1 Baseline characteristics

| Variable | Overall \( N = 1604 \) | Repair \( N = 1137 \) | Replacement \( N = 467 \) |
|----------|-------------------------|----------------------|------------------------|
| Age, years (mean ± SD) | 63 ± 13 | 61 ± 13 | 67 ± 11 |
| Female sex, N (%) | 770 (47.0) | 493 (43.4) | 277 (59.3) |
| Hypertension, N (%) | 940 (57.3) | 639 (56.2) | 301 (68.6) |
| Diabetes, N (%) | 167 (10.2) | 97 (8.5) | 70 (15.0) |
| COPD, N (%) | 155 (9.5) | 96 (8.4) | 59 (12.6) |
| Previous valve operations, N (%) | 156 (9.7) | 37 (3.3) | 119 (25.5) |
| Previous CABG, N (%) | 59 (3.7) | 30 (2.6) | 29 (6.2) |
| NYHA III–IV, N (%) | 545 (33.9) | 312 (27.4) | 233 (49.9) |
| NYHA EF \% (mean ± SD) | 538 (33.5) | 314 (27.6) | 224 (48.0) |
| Pulmonary Hypertension (≥60 mmHg) | 152 (9.5) | 84 (7.4) | 68 (14.5) |

### Table 2 Mitral valve pathology

| Mitral valve pathology | Overall \( N = 1604 \) | Repair \( N = 1137 \) | Replacement \( N = 467 \) |
|------------------------|-------------------------|----------------------|------------------------|
| Degenerative | 1114 (69.5 \%) | 907 (81.5 \%) | 207 (85.3 \%) |
| Functional | 191 (11.9 \%) | 136 (71.2 \%) | 55 (28.8 \%) |
| Reumathic | 151 (9.4 \%) | 17 (11.2 \%) | 134 (88.8 \%) |
| Endocarditis | 80 (5.0 \%) | 46 (57.5 \%) | 34 (42.5 \%) |
| Prosthesis dysfunction | 38 (2.4 \%) | 10 (26.3 \%) | 28 (73.7 \%) |
| Miscellaneous | 30 (1.9 \%) | 21 (70 \%) | 9 (30 \%) |

### Table 3 Early outcomes

| Variable | Overall \( N = 1604 \) | Repair \( N = 1137 \) | Replacement \( N = 467 \) |
|------------------------|-------------------------|----------------------|------------------------|
| In hospital Mortality | 19 (1.2 \%) | 4 (0.4 \%) | 15 (3.2 \%) |
| Stroke | 32 (2 \%) | 20 (1.8 \%) | 12 (2.6 \%) |
| RF requiring dialysis | 21 (1.3 \%) | 11 (1 \%) | 10 (2.1 \%) |
| New onset postoperative AF | 253 (15.8 \%) | 171 (15.0 \%) | 82 (17.6 \%) |
| Reoperation for bleeding | 78 (4.9 \%) | 48 (4.2 \%) | 30 (6.4 \%) |
| Ventilation time, h | 7 (5–11) | 7 (5–10) | 9 (6–15) |
| ICU stay, day | 1 (1–1) | 1 (1–1) | 1 (1–1) |
| Ward stay, day | 5 (4–7) | 5 (4–6) | 5 (4–7) |
| Discharged Home | 951 (59.3 \%) | 769 (67.6 \%) | 182 (39.0 \%) |
and 88.3 ± 2.2 %, 83.8 ± 3.8 % and 81.2 ± 4.5 % for those who had a bioprosthesis.

Reoperation
Overall freedom from reoperation was 98.6 ± 0.3 %, 94.7 ± 0.7 %, and 91.1 ± 1.7 % at 1-, 5-, and 10-years, respectively, Fig. 3a. After mitral valve repair, freedom from reoperation at 1-, 5- and 10-years was 98.4 ± 0.4 %, 94.8 ± 0.9 % and 93.6 ± 1.1 %, respectively. Freedom from reoperation after replacement at 1-, 5- and 10-years was 98.6 ± 0.6 %, 94.5 ± 1.6 % and 83.9 ± 5.5 % respectively, Fig. 3b.

In the setting of degenerative mitral valve disease, overall 1-, 5-, and 10-year freedom from repair was 99 ± 0.3 %, 96.3 ± 0.8 %, and 93.9 ± 1.3 % respectively, Fig. 3c. Specifically, rate of freedom from reoperation after mitral valve repair was 98.9 ± 0.3 % at 1 year,
96.4 ± 0.8 % at 5 years and 95.4 ± 1.1 % at 10 years, whereas after mitral valve replacement was 99.5 ± 0.5 % at 1 year, 95.8 ± 2.3 % at 5 year, and 91.3 ± 5.1 % at 10 year, respectively Fig. 3d.

Recurrent mitral regurgitation
Freedom from recurrent mitral regurgitation was 99 ± 0.4 % at 1 year, 95 % ± 1.3 % at 5 years and 86.6 % ± 3.8, Fig. 4a. In the setting of patients undergoing mitral valve repair for degenerative mitral valve disease, freedom from recurrent MR after 1, 5 and 10- years was 99 ± 0.6 % and 93.6 % ± 1.9 %, 86 % ± 4.9 %, Fig. 4b.

Discussion
We demonstrated that MIMVS through RT is a safe procedure, associated with excellent postoperative outcomes, short hospital length of stay and outstanding long-term results. Specifically, overall in-hospital mortality was 1.1 % lower than the recent mortality rate reported in the Society of Thoracic Surgeons Database and the low incidence of postoperative complications as
Fig. 4 a: Overall freedom from recurrent MR; b: freedom form recurrent MR in patients undergoing mitral valve repair for degenerative mitral valve disease.
Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality and experienced aortic dissection with the use of endoaortic balloon occlusion. It has been suggested that limited exposure may compromise probability of mitral valve repair when performing MIMVS. Overall, data from STS database and from the Euro Heart Survey indicate that the rate of valve repair in the US and Europe was 41 and 46.5 % respectively [19, 20]. Recently, Gammie reports a 67 % repair rate through median sternotomy and 85 % repair rate through minimally invasive access [14]. Many series have been published so far documenting excellent MIMVS repair rates (overall 81.2 %, on intention-to-repair basis 98.4 %), even in the setting of Barlow’s disease (94.5 and 100 %) [9, 21, 22]. We report 94 % repair rate of valves that were deemed amenable to repair and 94.7 % in the setting of degenerative valve disease; we are more keen to attribute repair failures to the complexity of the underlying disease rather than to insufficient exposure. In our series, low residual MR at discharge and outstanding freedom from reoperation indicate excellent standards of repair, in line with other studies, once again confirming that access through minithoracotomy does not interfere with quality and durability of valve repair [8, 9]. Finally, regarding the learning curve, a cross sectional survey on MIMVS concluded that at least more than 20 cases are required to gain familiarity with this procedure and at least one case needs to be performed per week to maintain proficiency [23]. Since 2005, in our institution, MIMVS has become the standard approach for the treatment of mitral valve disease. Therefore, due to the low numbers of standard sternotomy mitral procedures we have been forced to introduce young surgeons to mitral valve surgery directly through a minimally invasive approach. Recently a CUSUM analysis performed on seven surgeons has shown that MIMVS can be safely performed with low morbidity and mortality, even in mitral valve repair [24, 25].

The main limitation of this study is its retrospective nature; however our database is prospectively compiled. Although we reported excellent long-term results, echocardiographic data were not available for all patients. No information has been recorded regarding the aetiology of perioperative myocardial infarction as well as no information has been reported regarding the cause of late mortality. Finally we did not have the possibility to compare our series with a control group, as since the 2005 MIMVS is our standard approach, and patients demand less invasive procedures. Nevertheless a well-designed study with appropriate sample size is required to validate the advantages of MIMVS.

Conclusions
Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality and...
morbidity, high rate of mitral valve repair and excellent late results.

Abbreviations
MIMVS: minimally invasive mitral valve surgery; RT: right anterior minithoracotomy.

Competing interests
Dr Glauber, Ferrarini and Solinas have disclosure with Sorin. All other authors have no conflict of interest.

Authors’ contributions
MG: has participated in the conception and design of study, acquisition of data, analysis and interpretation of data; and has been involved in drafting of the manuscript. AM: has participated in the conception and design of study, acquisition of data, analysis and interpretation of data; and has been involved in drafting of the manuscript. MM: agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. DC: has participated in the conception and design of study, acquisition of data, has been involved in the revision of the manuscript. DG: involved in revising the manuscript critically for important intellectual content and in interpretation of data. MF: has participated in the conception and design of study, acquisition of data, has been involved in the revision of the manuscript. PAF: has participated in the conception and design of study, acquisition of data, interpretation of data and has been involved in drafting of the manuscript. AGC: has participated in the conception and design of study, acquisition of data, has been involved in the revision of the manuscript. ELQ: has been involved in reviewing the manuscript critically for important intellectual content and has given final approval of the version to be published. MS: has been involved in reviewing the manuscript critically for important intellectual content and has given final approval of the version to be published. All authors read and approved the final manuscript.

Received: 13 May 2015 Accepted: 23 November 2015
Published online: 07 December 2015

References
1. Gammie JS, Sheng S, Griffith BP, Peterson ED, Rankin JS, O’Brien SM, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87:1431–7.
2. Schmitto JD, Mokashi SA, Cohn LH. Minimally-invasive valve surgery. J Am Coll Cardiol. 2010;56:655–62.
3. Rosengart TK, Feldman T, Borger MA, Vassiliades TA, Gillinov M, Hoercher KJ, et al. Percutaneous and minimally invasive valve procedure: a scientific statement from the American Heart Association Council on Cardiovascular Surgery and Anesthesia, council on Clinical Cardiology, Functional Genomics and translational Biology Interdisciplinary Working Group, and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2008;117:1759–67.
4. Modi P, Hassan A, Chitwood WR. Minimally invasive mitral valve surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2008;34:943–52.
5. Falk V, Cheng DCH, Martin J, Diegeler A, Folliguet TA, Nifong LW, et al. Minimally invasive versus open mitral valve surgery: a consensus statement of the international society of minimally invasive coronary surgery (SMICS) 2010. Innovations. 2011;2:66–76.
6. Cheng DCH, Martin J, Lal A, Diegeler A, Folliguet TA, Nifong LW, et al. Minimally invasive versus conventional open mitral valve surgery. Innovations. 2011;6:84–103.
7. Cao C, Gupta S, Chandrakumar D, Nienaber TA, Indraratna P, Ang SC, et al. A meta-analysis of minimally invasive versus conventional mitral valve repair for patients with degenerative mitral disease. Ann Cardiothorac Surg. 2013;2:693–703.
8. Ding C, Jiang DM, Tao KY, Duan QJ, Li J, Kong MJ, et al. Anterolateral minithoracotomy versus median sternotomy for mitral valve disease: a meta-analysis. J Zhejiang Univ Sci B. 2014;15:522–32.
9. McClure RS, Athanassopoulos LV, McGurk S, Davidson MJ, Couper GS, Cohn LH. One thousand minimally invasive mitral valve operations early outcomes, late outcomes, and echocardiographic follow-up. J Thorac Cardiovasc Surg. 2013;145:1199–206.
10. Davierwala PM, Seeburger J, Planumueller B, Garbade J, Misfeld M, Borger MA. Minimally invasive mitral valve surgery: “The Leipzig experience”. Ann Cardiothorac Surg. 2013;2:744–50.
11. Volkoth M, Seeburger J, Garbade J, Borger MA, Misfeld M, Mohr FW. Conversion rate and contraindications for minimally invasive mitral valve surgery. Ann Cardiothorac Surg. 2013;2:853–4.
12. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.
13. Glauber M, Karimov JH, Farneti PA, Cerillo AG, Santarelli F, Ferrarini M, et al. Minimally invasive mitral valve surgery via right minithoracotomy. Multimedia Man Cardiothorac Surg 2009; doi:10.1510/mmcarts.2008.003350.
14. Gammie JA, Zhao Y, Peterson ED, O’Brien SM, Rankin SJ, Bartley PG. Less-invasive mitral valve operations: trends and outcomes from the Society of Thoracic Surgeons adult cardiac surgery database. Ann Thorac Surg. 2010; 90:1401–10.
15. Rtvick B, Chaudhuri K, Crouch G, Edwards JRW, Worthington M, Stuklis RG. Minimally invasive mitral valve procedures: the current state. Minimally invasive surgery 2013. Doi 10.11155/2013/679276.
16. Grossi EA, Loumet DF, Schwartz CF, Solomon B, Dells SL, Cullford AT. Minimally invasive mitral valve surgery with antegrade perfusion strategy is not associated with increased neurologic complications. Ann Thorac Surg. 2011; 92:1346–9.
17. Modi P, Rodriguez E, Hargrove 3rd WC, Hassan A, Szeto WY, Chitwood Jr WR. Minimally invasive video-assisted mitral valve surgery: a 12-year, 2-center experience in 1178 patients. J Thorac Cardiovasc Surg. 2009;137:1481–7.
18. Murzi M, Cerillo AG, Miceli A, Bevilacqua S, Kallushi E, Farneti P, et al. Anterograde and retrograde arterial perfusion strategy in minimally invasive mitral-valve surgery: a propensity score analysis on 1280 patients. Eur J Cardiothorac Surg. 2013;43:e167–172.
19. Bolling SF, Li S, O’Brien SM, Brennan JM, Prager RL, Gammie JS. Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg. 2010;90:1904–12.
20. Jung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–43.
21. Borger MA, Kaeding AF, Seebberger J, Mehnitchouk S, Hoebartner M, Winkelmann F, et al. Minimally invasive mitral valve repair in Barlow’s disease early and long-term results. J Thorac Cardiovasc Surg. 2014;148:379–85.
22. Murocetto C, Bisleri G, Bagazzi L, Repossini A, Berlinghieri N, Chian I. Results of minimally invasive, video-assisted mitral valve repair in advanced Barlow’s disease with bileaflet prolapse. Eur J Cardiothorac Surg. 2014. doi:10.1093/ ects/ezu166.
23. Misfeld M, Borger M, Byrne JG, Chitwood WR, Cohn LH, Galloway A, et al. Cross-sectional survey on minimally invasive mitral valve surgery. Annals Cardiothorac Surg. 2013;2:733–8.
24. Murzi M, Cerillo AG, Bevilacqua S, Gadaffi T, Kallushi E, Farneti P, et al. Enhancing departmental quality control in minimally invasive mitral valve surgery: a single-institution experience. Eur J Cardiothorac Surg. 2012;42:500–6.
25. Murzi M, Miceli A, Cerillo AG, Di Stefano G, Kallushi E, Farneti P, et al. Training surgeons in minimally invasive mitral valve repair: a single institution experience. Ann Thorac Surg. 2014;98:884–9.